Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Vanguard S&P 500 Growth Index Fund ETF (VOOG) Price & Performance

ACADIA Pharmaceuticals Inc.Trade
Vanguard S&P 500 Growth Index Fund ETFTrade

Price performance (Past 24H)

Key statistics

ACADIA Pharmaceuticals Inc. vs Vanguard S&P 500 Growth Index Fund ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.56 (market cap $5.07B), while Vanguard S&P 500 Growth Index Fund ETF trades at $85.07. Which is the better fit depends on your goals.

ACADVOOG
Market Cap
$5.07B
Sector
HealthBroad Market / Factor
52-Week High
$29.41$85.42
52-Week Low
$20.06$65.32
Enterprise Value
$4.19B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals (ACAD) trades at $29.39, up 0.62% on the day, with strong earnings momentum after Q2 2026 results beat expectations. The stock shows bullish technical signals from moving averages, though oscillators suggest potential overbought conditions. Revenue growth has been robust, rising from $517M in 2022 to $1.07B in 2025, with net income turning positive and margins expanding significantly. Recent news highlights FDA Fast Track designation for remlifanserin and raised 2026 revenue guidance.

Outlook remains positive driven by product sales growth and pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Analyst consensus is strongly bullish with a $33.89 price target, indicating ~15% upside. Investment appeal hinges on execution of commercial strategy and successful drug development.

Vanguard S&P 500 Growth Index Fund ETF

VOOG trades at $85.18, down slightly by 0.02% today. Technical indicators show a bullish trend with moving averages supporting upside momentum, though the relative strength index suggests potential overbought conditions near-term. Recent news highlights institutional accumulation, including Apella Capital increasing holdings by 463.2% as of August 2026, and the ETF hitting a new 52-week high, reflecting strong investor interest in large-cap growth exposure.

The outlook remains positive given the ETF's low expense ratio of 0.07% and focus on S&P 500 growth stocks, but risks include high concentration in technology sectors and sensitivity to market volatility. Continued institutional inflows and bullish technical signals support further gains, though overbought levels warrant caution.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.

Read more on ACAD

About Vanguard S&P 500 Growth Index Fund ETF

VOOG is an index-based ETF that tracks the S&P 500 Growth Index, composed of the growth-oriented companies within the S&P 500. It selects constituents based on three key metrics—sales growth, the ratio of earnings change to price, and momentum—offering a highly liquid and low-cost way to capture the high-performing 'growth slice' of the broader U.S. large-cap market.

Read more on VOOG